News

Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific

Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies TAIPEI, Taiwan, Jan. 09, 2025 (GLOBE NEWSWIRE)…

12 months ago

KFSHRC’s Study Named Among Top 10 Most Impactful Papers of 2024

RIYADH, Saudia Arabia, Jan. 09, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has solidified its…

12 months ago

Philips appoints Jie Xue as Chief Business Leader Precision Diagnosis, co-leader of the Diagnosis & Treatment segment, and Özlem Fidanci as Chief of International Region

Jie Xue Özlem Fidanci January 9, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader…

12 months ago

Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025

Oslo, January 9, 2025: Ultimovacs ASA held its extraordinary general meeting today January 9, 2025. All the matters on the…

12 months ago

MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director

OXFORD, United Kingdom, Jan. 09, 2025 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor…

12 months ago

Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines

Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US…

12 months ago

MONCYTE Health Joins International Consortium for Earlier Diagnosis and Management of Familial Hypercholesterolemia

EUR 7 million Horizon Europe funded FH-EARLY project on world’s most common inherited metabolic disorderHELSINKI, Jan. 09, 2025 (GLOBE NEWSWIRE)…

12 months ago

Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program…

12 months ago

ONWARD Medical Announces First Commercial Sales of ARC-EX System

UW Medicine and Next Steps Chicago both purchased systems in late December 2024 ARC-EX is the first and only FDA approved…

12 months ago

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added…

12 months ago